Amgen reported stable quarterly revenues and modest EPS growth, coupled with positive guidance for 2010 despite regulatory uncertainties surrounding Prolia. Managementâ€™s focus on pipeline advancements and cost management provides confidence, but concerns about FDA approvals and Aranesp sales may limit immediate stock gains. The balanced outlook suggests a cautiously positive short-term impact.

[1]